Esgerd-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD) and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), selectively inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant and prolonged reduction in gastric acid secretion. This dual-action mechanism provides symptomatic relief and promotes mucosal healing in erosive esophagitis and peptic ulcer disease. Esgerd-DSR is indicated for patients requiring both acid suppression and prokinetic therapy to optimize therapeutic outcomes. The combination capsule should be administered as prescribed, typically before meals, to maximize efficacy. Caution is advised in patients with known hypersensitivity to either component, and it should be used with care in individuals with underlying cardiac conditions due to potential QT interval prolongation associated with Domperidone. Regular monitoring and adherence to recommended dosage are essential to minimize adverse effects and ensure optimal clinical benefit.